Mobile app and smart-label support to help people take oral cancer medicines

Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy: A Pilot Feasibility Clinical Trial

NA · University of California, Irvine · NCT07073807

This 3-month pilot will try a mobile app with smart pill labels to track doses, symptoms, and financial or social needs for English- and Spanish-speaking adults who recently started oral anticancer medications to help them take their medicines as prescribed.

Quick facts

PhaseNA
Study typeInterventional
Enrollment35 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity of California, Irvine (other)
Locations5 sites (Irvine, California and 4 other locations)
Trial IDNCT07073807 on ClinicalTrials.gov

What this trial studies

This is a single-arm, 3-month pilot enrolling 30 English- or Spanish-speaking adults with any cancer who have a new prescription for oral anticancer therapy and receive care at UCI-affiliated clinics. All participants will use the TAPPT® web-based app with smart labels (near-field communication) to enable real-time adherence tracking, symptom monitoring, tailored reminders, educational content, and links to financial and social resources. The trial is stratified by age (<65 and ≥65) and focuses on feasibility, acceptability, and identification of barriers and facilitators to using the mHealth intervention. Study staff will collect usage data and participant feedback to inform future larger trials and refinements to the intervention.

Who should consider this trial

Good fit: Adults (18+) with any type or stage of cancer treated at UCI Chao Family Comprehensive Cancer Center–affiliated clinics who speak English or Spanish, own a smartphone, and have a new oral anticancer prescription started within the past 90 days or planned within 15 days.

Not a fit: Patients with ECOG performance status >2, those unable to consent or participate due to medical or cognitive limitations, participants in another adherence-monitoring trial, or individuals without a smartphone are unlikely to benefit from this intervention.

Why it matters

Potential benefit: If successful, the intervention could improve medication adherence and early symptom management while connecting patients to financial and social support, potentially improving treatment continuity and outcomes.

How similar studies have performed: Previous efforts to improve oral anticancer adherence have produced mixed results, and while some mHealth pilot programs have shown promise, definitive evidence remains limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Must speak English or Spanish
* Must be 18 years of age or older
* Have a diagnosis of any type and stage of cancer
* Have a new prescription for an oral anticancer therapy (OAT) initiated within the last 90 days or planned to start within the next 15 days
* Be receiving treatment at UCI Chao Family Comprehensive Cancer Center-affiliated oncology clinics
* Own a smartphone and be willing to receive study-related text messages.

Exclusion Criteria:

* Have an Eastern Cooperative Oncology Group (ECOG) performance status greater than 2
* Be medically or cognitively unable to give consent or participate in the study
* Be participating in another clinical trial that monitors adherence or symptoms related to the newly prescribed OAT

Where this trial is running

Irvine, California and 4 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Cancer, Neoplasms, Oral Anticancer Therapy, Medication Adherence, Mobile Health, Health Literacy, Symptom Management, Health-Related Social Needs

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.